Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.59. Xtant Medical shares last traded at $0.56, with a volume of 37,022 shares trading hands.
Xtant Medical Stock Up 0.3 %
The company has a market cap of $83.21 million, a PE ratio of -4.60 and a beta of 0.35. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.
Institutional Investors Weigh In On Xtant Medical
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its stake in Xtant Medical by 70.2% during the 3rd quarter. Geode Capital Management LLC now owns 515,006 shares of the medical device company's stock worth $348,000 after buying an additional 212,394 shares during the period. Renaissance Technologies LLC increased its stake in Xtant Medical by 15.0% during the 4th quarter. Renaissance Technologies LLC now owns 798,033 shares of the medical device company's stock worth $354,000 after buying an additional 103,825 shares during the period. Finally, Evernest Financial Advisors LLC purchased a new stake in Xtant Medical during the 3rd quarter worth approximately $27,000. 69.33% of the stock is owned by hedge funds and other institutional investors.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Stories
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
